Effects on cardiac, renal, and vascular endothelial markers after switching to topiroxostat from febuxostat treatment among IGT patients

Not Applicable

• Conditions: Hyperuricemic patients complicated with impaired glucose tolerance (IGT)

• Registration Number: JPRN-UMIN000018139
• Lead Sponsor: Diabetes and Lifestyle Center, Tomonaga Clinic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who fall into any of the following conditions are excluded: 1. Have a history of hypersensitiveness to topiroxostat, febuxostat, or allopurinol 2. Currently on mercaptopurine hydrate (including those who plan to use) 3. Currently on azathioprine (including those who plan to use) 4. Cancer-carrying (excepts for those completely cured) 5. ALT or AST value is twice higher than the standard value set by each institution 6. Complicated with chronic hepatitis (type B or C) and classified as active 7. Complicated with hepatic cirrhosis 8. Other conditions that may be judged by a (responsible) investigator to be inappropriate to this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified